Start-up company brings BioSOLVE Curcumin mono ingredient to market

Zeus has already successfully developed a number of patent-filed platform manufacturing technologies and added-value ingredients backed by clinical, preclinical and other scientific studies

Zeus has recently launched BioSOLVE Curcumin, a rapidly dispersible bioavailable and clinically studied curcumin product.

BioSOLVE Curcumin comes with the advantage of being manufactured as a “mono ingredient” soluble matrix technology, ensuring significant therapeutic benefits at a very minimal daily intake.

This could eventually benefit end users by reducing the daily dose burden.

BioSOLVE Curcumin has shown significant reductions in pain, joint stiffness, improved physical function and decreased swelling when studied in rheumatoid arthritis patients.

The product was recently launched commercially in multiple countries across globe, including the US.

“Zeus Hygia is a company founded by passionate researchers, science and sustainable innovations in the nutraceutical domain."

"Our core mission is to bring more added-value ingredients to market using a holistic approach and proven therapeutic benefits, which can help the public to remain maintain healthy and focus on preventive well-being,” said Mr Arunkanth Krishnakumar, cofounder and Director.

Companies